CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
联合 PNI-HB 免疫营养指数在复发/难治性非霍奇金淋巴瘤 CD19 CAR-T 细胞治疗中的预后价值
英文原题：The prognostic utility of a combined PNI-HB immunonutritional index in CD19 CAR T-cell therapy for relapsed/refractory non-Hodgkin lymphoma.
查看英文原题
The prognostic utility of a combined PNI-HB immunonutritional index in CD19 CAR T-cell therapy for relapsed/refractory non-Hodgkin lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD19嵌合抗原受体（CAR）T细胞疗法改善了复发/难治性非霍奇金淋巴瘤（R/R NHL）的结局。然而，复发和治疗相关毒性仍然常见，凸显了对预后生物标志物的需求。
本研究在一个107例患者的队列中评估了一种复合免疫营养指数，该指数整合了预后营养指数（PNI）和血红蛋白（HB）。采用Cox比例风险模型、时间依赖性受试者工作特征分析和bootstrap验证对PNI-HB进行评估。PNI-HB评分独立预测较差的PFS（HR = 1.34，95% CI，1.08-1.66；p = 0.009），并将患者分层为结局不同的风险组。该模型优于IPI，具有更低的AIC/BIC值（AIC/BIC = 8.97）和更好的区分度。较高的PNI-HB评分与细胞因子释放综合征（CRS）风险增加相关（OR = 1.86，p = 0.004）。PNI-HB评分是一种用于预测接受CD19 CAR-T 细胞治疗患者生存和毒性的非侵入性工具。
展开英文摘要原文
CD19 chimeric antigen receptor (CAR) T cell therapy has improved outcomes in relapsed/refractory non-Hodgkin lymphoma (R/R NHL).
However, relapse and treatment related toxicities remain common, highlighting the need for prognostic biomarkers.
This study evaluates a composite immunonutritional index, integrating the prognostic nutritional index (PNI) and hemoglobin (HB) in a cohort of 107 patients. The PNI-HB was assessed using Cox proportional hazards models, time-dependent receiver operating characteristic analysis, and bootstrap validation. The PNI-HB score independently predicted inferior progression-free survival (HR = 1. 34, 95% CI, 1. 08-1.
66; p = 0. 009) and stratified patients into risk groups with distinct outcomes. The model outperformed IPI, with lower AIC/BIC values ( AIC/ BIC = 8. 97) and improved discrimination. Higher PNI-HB scores were associated with increased risk of cytokine release syndrome (OR = 1. 86, p = 0. 004). The PNI-HB score is a non-invasive tool for predicting survival and toxicity in patients receiving CD19 CAR T cell therapy.
论文信息
- 作者
- Liu Y、Chen X、Li P、Hao W、Luo X、Zhang W、Lu H、Xue B
- 单位
- Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.China
- 期刊
- iScience2026 Apr 17
- 原文标识
- PubMed 41890967 · DOI 10.1016/j.isci.2026.115253
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →